-
PD-1 new partner: BeiGene introduces LAG-3 antibody for US$772 million
Time of Update: 2022-01-11
In late March, BMS announced that the drug will be used in combination with the PD-1 monoclonal antibody Opdivo (nivolumab) to achieve the primary endpoint of PFS in the treatment of metastatic or unresectable melanoma initially treated patients with phase II/III clinical trials .
-
The first anti-FcRn monoclonal antibody was approved by the FDA for marketing!
Time of Update: 2022-01-11
Text: Picking up shellsOn December 17, Argenx announced that the US FDA approved VYVGART™ (efgartigimod alfa-fcab) for the treatment of adult systemic myasthenia gravis (gMG) with positive anti-acetylcholine receptor (AChR) antibodies .
-
TJ-CD4B bispecific antibody TJ-CD4B is approved for Phase 1 clinical trial in China
Time of Update: 2022-01-11
On December 15th, TJBio announced that CDE has officially approved the bispecific antibody TJ-CD4B (also known as ABL111) to treat solid tumors (including gastric cancer, esophageal-gastric junction adenocarcinoma, esophageal adenocarcinoma, and pancreatic duct adenocarcinoma).
-
The US claims that Biden signed sanctions against entities and individuals in 4 countries, including 4 Chinese pharmaceutical companies and 1 individual
Time of Update: 2022-01-11
S. Department of the Treasury website, the U.
S. 's so-called sanctions are based on combating drug abuse and addiction problems such as fentanyl, and it is accused of these companies and individuals "participating in the global illegal drug trade .
-
China Cell Holding Subsidiary Submits Adalimumab Biosimilar Drug Listing Application
Time of Update: 2022-01-11
On December 16, China Cell Engineering, a holding subsidiary of China Cell Biology Group, submitted an application for the listing of Adalimumab (SCT630) biosimilar drug . SCT630 is a recombinant ful
-
Dismal performance, side effects... Can Bojian Aduhelm cut its price by 50% to open up the market?
Time of Update: 2022-01-11
Bojian’s unexpected favor this time stems from the pressure it faces from multiple sources: sales are not satisfactory, the pharmaceutical industry has many doubts about the effect of Aduhelm, reports of possible side effects, and waiting for the underwriting decision of medical insurance.
-
Tasly’s wholly-owned subsidiary, Memantine Hydrochloride Sustained-Release Capsules Obtained Drug Registration Certificate
Time of Update: 2022-01-11
On December 21, Tasly issued an announcement stating that its wholly-owned subsidiary, Diyi Pharmaceutical, had issued the Drug Registration Certificate for Memantine Hydrochloride Sustained Release Capsules approved and issued by the National Medical Products Administration for the treatment of moderate to severe Alzheimer’s.
-
Biogen/Eisai's Alzheimer's disease drug Aduhelm was rejected by the European Union!
Time of Update: 2022-01-11
Recently, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has formally given a negative opinion on the marketing authorization application of Biogen and its partner Eisai for the application of the monoclonal antibody drug Aduhelm for the treatment of early Alzheimer's disease (AD) .
-
The details of the Phase 3 study of K medicine + Lenva's failure are released!
Time of Update: 2022-01-11
Following KN189, is the new immunotherapy combination therapy expected to redefine the ceiling of the first-line treatment of NSCLC?LEAP-007: Coke combination ushered in the first failure of Phase III studyLEAP-007: Coke combination ushered in the first failure of Phase III studyIn the past, in phase Ib/II, open-label, one-arm trials (study code 111/KEYNOTE-146, NCT02501096), drug K + lenvatinib showed encouraging results in patients with metastatic NSCLC (n=21) Anti-tumor activity (ORR 33%, median PFS 5.
-
Qilu won 1 billion injections
Time of Update: 2022-01-11
A few days ago, the official website of the State Food and Drug Administration showed that Qilu Pharmaceutical's recombinant human follicle stimulating hormone for injection was approved for marketing.
-
Zai Lab's Omacycline is approved and Hisun Pharmaceutical has the right to promote in China soon
Time of Update: 2022-01-11
ZL-2401 p-toluenesulfonate (Omadacycline, omacycline tosylate) is a new type of 9-aminomethylcycline drug, after chemical group modification based on the tetracycline antibiotic minocycline The resulting semi-synthetic compound has broad-spectrum antibacterial activity.
-
Junshi Biologics was approved for subcutaneous injection of PD-1
Time of Update: 2022-01-10
Pre-clinical in vivo pharmacodynamic tests have shown that JS001sc has a significant tumor-inhibiting effect in animal models when administered by subcutaneous injection.
3 mg/kg, JS001sc administered by subcutaneous injection and Terry administered by intravenous injection The anti-tumor effect of prilimumab was equivalent, and no significant difference was seen .
-
Merck's oral new crown drug Molnupiravir receives FDA emergency use authorization
Time of Update: 2022-01-10
On December 23, Merck/Ridgeback announced that the oral new crown drug Molnupiravir (MK-4482/EIDD-2801) has received emergency use authorization from the US FDA for the treatment of adult patients with mild to moderate COVID-19 .
-
Another HIV drug clinical study was suspended by the U.S. FDA this time from Gilead
Time of Update: 2022-01-10
CompilenewbornFollowing Merck’s islatravir, another HIV drug in research has encountered a clinical suspension by the US FDA, this time from Gilead .
On December 22, Gilead issued an announcement stating that as many as 10 clinical trials of its injectable HIV drug candidate lenacapavir were suspended by the US FDA .
-
Diabetes drugs have two more benefits, or to achieve both specimens
Time of Update: 2022-01-10
It is understood that in order to better benefit patients, many pharmaceutical companies in China are actively deploying innovative development of diabetes drugs .
According to reports, Suparutide (long-acting human-derived GLP-1), an innovative diabetes drug of Yinnuo Medicine, is currently undergoing clinical phase 3 research.
-
Domestic innovative drug companies are ushering in an intensive harvest period!
Time of Update: 2022-01-10
In recent years, with the successive release of a series of favorable pharmaceutical innovation policies such as speeding up the review and approval of new drugs, as well as the high R&D investment of local innovative drug companies, the continuous breakthroughs in key technologies have made domestic innovative drug companies usher in an intensive harvest period.
-
Looking forward to 2022, the pharmaceutical equipment industry will press the "shift button"!
Time of Update: 2022-01-10
In China’s pharmaceutical market, in recent years, with the continuous improvement of the living standards of our residents, the intensified population aging, and the promotion of a series of favorable pharmaceutical innovation and development policies, the continuous growth of R&D investment by local pharmaceutical companies has led to the rapid growth of domestic innovative drugs and emerging drugs.
-
Tonghua Dongbao soluble sweetener lispro double insulin injection application clinically accepted
Time of Update: 2022-01-10
On December 27, Tonghua Dongbao issued an announcement stating that the company had recently obtained a notice on clinical trial application acceptance for soluble glorine-lispro insulin injection (THDB0207 injection) issued by CDE .
-
Maiwei Biologics Submits Marketing Applications for 2 Biosimilar Drugs of Disulumab
Time of Update: 2022-01-10
, And a comparative study of effectiveness and safety in patients with bone metastases from solid tumors.
Retrieved Dec 21, 2021, from https:// The marketing application of 9MW0311, a biosimilar drug of Desulumab injection by Maiwei Biologics, was accepted.
-
A large number of enterprises will benefit from the publication of documents in various places to promote the development of the Chinese medicine industry
Time of Update: 2022-01-10
With the help of these policies, the industry expects that a large number of traditional Chinese medicine companies will usher in a larger market space and move toward a higher-quality development path through continuous inheritance of the essence, integrity and innovation .
